A5023092047- Astro and Planetary Science
- Lymphoma Diagnosis and Treatment
- Planetary Science and Exploration
- Isotope Analysis in Ecology
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Viral-associated cancers and disorders
- CNS Lymphoma Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Geological and Geochemical Analysis
- Sarcoma Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- Chronic Lymphocytic Leukemia Research
- Eosinophilic Disorders and Syndromes
- High-pressure geophysics and materials
- Hematological disorders and diagnostics
- Kruppel-like factors research
- Nuclear Physics and Applications
- Cytokine Signaling Pathways and Interactions
- Geology and Paleoclimatology Research
- Chronic Myeloid Leukemia Treatments
- Childhood Cancer Survivors' Quality of Life
- Lung Cancer Treatments and Mutations
- T-cell and Retrovirus Studies
- Ancient Near East History
- Paleontology and Stratigraphy of Fossils
SUNY Upstate Medical University
2010-2021
Hackensack University Medical Center
2016
Children's Oncology Group
2007-2016
Princess Margaret Cancer Centre
2016
University of Rochester
2016
University of Michigan
2016
City Of Hope National Medical Center
2015
City of Hope
2015
Pfizer (United Kingdom)
2015
Roche (Switzerland)
2015
The Children's Oncology Group study AHOD0031, a randomized phase III study, was designed to evaluate the role of early chemotherapy response in tailoring subsequent therapy pediatric intermediate-risk Hodgkin lymphoma. To avoid treatment-associated risks that compromise long-term health and maintain high cure rates, dose-intensive with limited cumulative doses used.Patients received two cycles doxorubicin, bleomycin, vincristine, etoposide, cyclophosphamide, prednisone (ABVE-PC) followed by...
To determine the oncologic efficacy, cardioprotective effectiveness, and safety of dexrazoxane added to chemotherapy that included a cumulative doxorubicin dose 360 mg/m(2) treat children adolescents with newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL) or non-Hodgkin lymphoma (L-NHL).Patients were treated on Pediatric Oncology Group Protocol POG 9404, which random assignment treatment without given as bolus infusion immediately before every doxorubicin. Cardiac effects assessed...
PURPOSE Therapy of hairy cell leukemia has markedly improved. Interferon alfa-2a and pentostatin are active agents. The National Cancer Institute organized an intergroup trial to compare these agents prospectively in untreated patients. METHODS Patients were randomized receive either interferon (3 x 10(6) U subcutaneously three times per week) or (4 mg/m2 intravenously every 2 weeks). who did not respond initial treatment crossed over. RESULTS Of 356 patients on study, 313 eligible. Among...
The Pediatric Oncology Group adopted a histology-based approach to non-Hodgkin's lymphoma and treated patients with advanced large-cell on separate protocol (doxorubicin, vincristine, prednisone, 6-mercaptopurin, methotrexate; APO regimen). In this study, we assessed the effects of an intense antimetabolite therapy alternating overall survival (OS) event-free (EFS) looked into biologic correlates.From December 1994 April 2000, enrolled 180 eligible pediatric stage III/IV (LCL); 90 were...
Abstract Background Hodgkin lymphoma is highly curable but associated with significant late effects. Reduction of total treatment would be anticipated to reduce This aim this study was demonstrate that a reduction in possible without compromising survival outcomes. Methods Protocol P9426, response‐dependent and reduced for low risk (stages I, IIA, IIIA 1 ) designed 1994 based on previous pilot project. Patients were enrolled from October 15, 1996 September 19, 2000. randomized receive or not...
Jak2, a member of the Janus kinase family nonreceptor protein tyrosine kinases, is activated in response to variety cytokines, and functions survival proliferation cells. An activating JAK2V617F mutation has been found most patients with myeloproliferative neoplasms, treated Jak2 inhibitors show significant hematopoietic toxicities. However, role adult stem cells (HSCs) not clearly elucidated. Using conditional knockout allele, we have that deletion results rapid loss HSCs/progenitors...
Children's Oncology Group study AHOD03P1 was designed to determine whether excellent outcomes can be maintained for patients with low-risk, pediatric lymphocyte-predominant Hodgkin lymphoma (LPHL) a strategy of resection alone or minimal chemotherapy.Patients stage IA LPHL in single node that completely resected were observed without further therapy; recurrences treated three cycles doxorubicin/vincristine/prednisone/cyclophosphamide (AV-PC). Patients unresected IIA AV-PC. less than complete...
The case described below is of interest, not only because its rarity, but also the patient had been observed over a large number years.Primary carcinoma liver finally supervened, and absence ascites throughout illness was an unusual feature.The autopsy findings, pathological fact that occlusion hepatic veins rarely if ever occurs in non-syphilitic cirrhosis, have led us to present as one primary veins, with secondary fibrosis liver.Clinical report.The clinical records this extend years 1906...
Estimates are made of the abundances some lithophile trace elements, particularly heat-producing in bulk Earth. The applicability abundance estimates based on extra-terrestrial analogues, and terrestrial heat flow data discussed. Sr, Nd Pb isotope briefly reviewed used to identify basalt source regions mantle which have been depleted or enriched these other elements. An assessment is role silicate liquid transfer production mantle. timing event(s) can be constrained using Rb-Sr, Sm-Nd U-Pb...
Background Early response to initial chemotherapy in Hodgkin lymphoma (HL) measured by computed tomography (CT) and/or positron emission (PET) after two three cycles of may inform therapeutic decisions. Risk stratification at diagnosis could, however, allow earlier and potentially more efficacious treatment modifications. Patients Methods We developed a predictive model for event-free survival (EFS) pediatric/adolescent HL using clinical data known from 1103 intermediate-risk patients...